U.S. Retail Distributors Stock News

WEX (WEX) has drawn attention after its shares closed at $161.88, with recent returns over the past week, month, and past 3 months giving investors fresh context for its current valuation. See our latest analysis for WEX. The recent 1-day share price return of 1.83% and 7-day share price return of 9.09% come after a year where the 1-year total shareholder return declined 4.96%. This suggests short term momentum is picking up while longer term returns have been weaker. If WEX has you...

Harbour’s appointment as operator of the Zama project in Mexico marks an important shift for Talos Energy (TALO), given Zama’s role in the company’s portfolio and in its future development plans. See our latest analysis for Talos Energy. The Zama operatorship shift comes at a time when Talos Energy’s share price has retreated in the short term, with a 30 day share price return decline of 9.21%, even as the 90 day share price return of 19.65% and 1 year total shareholder return of 1.88% point...

In early January 2026, Arcellx, Inc. filed a US$209.19 million shelf registration for 3,208,367 common shares tied to an ESOP-related offering, while continuing to advance its immunotherapy pipeline and collaboration with Kite Pharma. Fresh positive analyst coverage, highlighting Arcellx’s lead multiple myeloma candidate and its partnership with Kite Pharma, has drawn greater attention to the company’s approach to cell-based cancer treatments. Next, we’ll examine how this upbeat analyst...

If you are wondering whether Arch Capital Group at around US$95 a share offers good value today, the key question is how its current price lines up with what the business may be worth. The stock has posted returns of 1.4% over the last 7 days, 3.7% over the last 30 days, 1.4% year to date, 5.6% over 1 year, 57.0% over 3 years and 188.5% over 5 years, which has put valuation firmly on many investors' radar. Recent attention on Arch Capital Group has been supported by ongoing coverage of the...

MannKind Corporation recently released a business update outlining past progress and key upcoming regulatory milestones, including anticipated 2026 FDA decisions on an Afrezza label update, a supplemental Biologics License Application for pediatric use, and a supplemental New Drug Application for the FUROSCIX ReadyFlow Autoinjector, alongside advances in its inhaled therapy pipeline. A particularly important development is the alignment of multiple regulatory review timelines across Afrezza...

Leadership shakeup puts technology and regional focus in the spotlight Timken (TKR) is reworking its leadership chart, appointing a new chief technology officer and creating regional president roles. This move puts technology, AI and geographic execution more squarely in focus for shareholders. See our latest analysis for Timken. These leadership changes come after a strong run in the shares, with a 90 day share price return of 28.79% and a 1 year total shareholder return of 27.83%. This...

In recent days, FedEx has been highlighted for its pivot toward higher-value business-to-business shipping in sectors such as automotive, healthcare, and aerospace, supported by cost reduction efforts like DRIVE and Network 2.0 despite temporary operational headwinds. An interesting angle is how nearly half of FedEx’s latest quarterly revenue growth came from B2B customers, underlining the growing importance of these premium verticals for its global logistics model. We’ll now examine how...

SolarEdge Technologies (SEDG) has drawn fresh attention after recent share price moves, with the stock up around 9% over the past week and modestly positive over the past month despite weaker performance over the past 3 months. See our latest analysis for SolarEdge Technologies. At a share price of $32.89, SolarEdge’s recent 1-day and 7-day share price returns of 8.69% and 4.88% stand against a 90-day share price return of 6.19% and a 1-year total shareholder return of 123.59%. Recent...

JPMorgan recently downgraded Fidelis Insurance Holdings from Neutral to Underweight on concerns about its competitive position and reliance on the Fidelis Partnership, even as other analysts remain divided following strong Q3 2025 results. Separately, Fidelis announced it will release its Q4 2025 financial results on February 25, 2026, followed by an investor call, giving the market fresh information to reassess these differing views on the business. We’ll now examine how JPMorgan’s concerns...

In recent days, EverCommerce reported quarterly results that missed revenue expectations and led management to lower full-year guidance, even as the company achieved profitability and outperformed on adjusted EBITDA, while President Matthew Feierstein continued his pattern of selling 25,000 shares in open-market transactions. At the same time, EverCommerce acquired AI platform ZyraTalk to bolster its SaaS capabilities and expanded its share repurchase authorization by US$50.00 million,...

If you are wondering whether Cigna Group's current share price reflects its underlying value, you are not alone. This article is built to help you frame that question clearly. The stock recently closed at US$278.95, with returns of 6.2% over the last 30 days, 2.0% over the past year and 39.3% over five years. The shorter 7 day and year to date periods both sit at a 0.1% decline. Recent news around Cigna Group has focused on its role as a large managed care and health services provider, with...

Satellogic (SATL) shares are in focus after the company announced a seven figure agreement with a customer that wants continuous, high frequency Earth observation coverage across a broad set of priority sites. See our latest analysis for Satellogic. The agreement comes after a volatile period for Satellogic, with a 7 day share price return of 53.57% and 30 day share price return of 46.83%, contrasting with a 90 day share price return decline of 11.21% and a 3 year total shareholder return...

First Commonwealth Financial (FCF) has been in focus after Raymond James raised its rating to Outperform, alongside a new US$25 million share repurchase program and a Board expansion that adds cybersecurity and regulatory expertise. See our latest analysis for First Commonwealth Financial. At a share price of US$17.26, First Commonwealth Financial has seen a 7.27% 90 day share price return. Its 1 year total shareholder return of 12.28% and 5 year total shareholder return of 61.68% suggest...

PriceSmart (PSMT) just reported its fiscal first quarter results, with revenue of US$1.38b, net income of US$40.17m and earnings per share of US$1.29. The update put costs and growth plans in sharper focus for investors. See our latest analysis for PriceSmart. At a share price of US$134.45, PriceSmart has seen momentum build recently, with a 7 day share price return of 9.0% and a 1 year total shareholder return of 52.6%, alongside expansion plans in Central and South America. If this earnings...

Huntington Ingalls Industries (HII) recently hosted top U.S. Navy leaders at its Ingalls Shipbuilding division to review workforce efforts and next generation ship programs, a development that has coincided with increased market interest in the stock. See our latest analysis for Huntington Ingalls Industries. The recent visit by senior Navy leaders comes as Huntington Ingalls Industries’ 90 day share price return of 36.75% and 1 year total shareholder return of 108.43% signal building...

Guidewire Software (GWRE) is back in focus after the company completed a US$400 million share repurchase plan and its board approved a new US$500 million buyback authorization funded from internal resources. See our latest analysis for Guidewire Software. The new US$500 million buyback comes after a sharp pullback, with a 30 day share price return of 7.69% and a 90 day share price return of 22.56% contrasting with a 1 year total shareholder return of 8.28% and a very large 3 year total...

In recent days, Centessa Pharmaceuticals received upbeat analyst coverage after confirming that its lead candidate ORX750 showed potential best-in-class efficacy in treating Narcolepsy types 1 and 2 and Idiopathic Hypersomnia, with major clinical expansion planned from early 2026. This combination of positive clinical signals and expanding development plans has strengthened the perception of ORX750 as a potentially differentiated asset in the sleep-disorder treatment landscape. Next, we’ll...

Haoxin Holdings Limited ( NASDAQ:HXHX ) shareholders are no doubt pleased to see that the share price has bounced 31...

Key Insights Institutions' substantial holdings in Lexeo Therapeutics implies that they have significant influence over...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Despite an already strong run, Bridger Aerospace Group Holdings, Inc. ( NASDAQ:BAER ) shares have been powering on...

Key Insights The projected fair value for Legacy Housing is US$27.17 based on 2 Stage Free Cash Flow to Equity Current...

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...

Zeta Global Holdings Corp. ( NYSE:ZETA ) shares have continued their recent momentum with a 25% gain in the last month...